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Abstract 
Objectives. To assess the association between the blood level of tacrolimus (TAC) in patients with 
connective tissue disease (CTD) and CYP3A5 polymorphism that affects TAC level in patients of 
organ transplantation. 
 
Methods. 72 patients with CTD were genotyped for rs776746 in CYP3A5. The blood trough level of 
TAC after taking 3mg/day was retrospectively obtained for each patient.  
 
Results. Allele A of rs776746 showed a significant association with a decreasing serum level of TAC 
(p=0.0038). One copy of the A allele decreased the level of TAC on average by 21.2%.  
 
Conclusions. Rs776746 is associated with levels of TAC level in a dose-dependent manner in 
patients with CTD. 
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Introduction 
Tacrolimus (FK506, TAC) is a calcineurin inhibitor isolated from Streptomyces tsukubaensis (1) and 
one of the many types of powerful immunosuppressants that are frequently used for solid organ 
transplantation to prevent organ rejection(2). TAC is also used for patients with connective tissue 
disease (CTD) including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), 
polymyositis (PM) and dermatomyositis (DM) to control disease activity(3, 4). TAC is metabolized 
mainly by cytochrome P450 (CYP) 3A in the liver and intestine(5). Because TAC level is highly 
variable among patients, to predict TAC level to achieve therapeutic effect is a big challenge. 
Previous studies revealed that the variation of TAC level is largely attributable to different 
expressions of CYP3A in patients of organ transplantation. Patients carrying CYP3A5*3 determined 
by the G allele of rs776746 were shown to have high TAC level than patients with the A allele(5, 6).  
Although TAC is a substrate for P-glycoprotein encoded by the ABCB1 gene, effects of 
polymorphisms in ABCB1 on TAC level is inconclusive(6, 7).  Genetic studies have only been 
performed recruiting patients with organ transplantation to date. 
When TAC is given to patients with CTD, the dosage is around 3mg/day (3, 4) which is much 
lower than that given to patients of organ transplantation. For example, patients with renal 
transplantation receive 0.3mg/kg/day around the transplantation and 0.12mg/kg/day as maintainance 
(8). In addition, though recipients of renal transplantation take TAC twice daily(8), patients with 
CTD only take a single dose of TAC per day.  The effect of CYP3A5 on TAC levels with low TAC 
exposure has not been studied so far. Furthermore, chronic, systemic and autoimmune inflammatory 
process in CTD may influence the metabolism and level of TAC. Thus, whether the associations 
between polymorphisms of CYP3A5 and TAC levels can be observed in patients with CTD remained 
unclear. Evidence of the association between CYP3A5 and TAC levels in patients with CTD would 
enable us to develop a predictive model of TAC levels in these patients. Here, we performed an 
association study to address this point. 
 
Materials and Methods 
This study was designed in accordance with the Helsinki Declaration. This study was approved by 
the ethics committee of Kyoto University Graduate School and Faculty of Medicine. Written 
informed consent was obtained from all the participants. 
 
Study Subjects  
A total of 72 subjects with CTD who were prescribed to take a single dose of TAC every day in the 
evening at the Department of Rheumatology and Clinical Immunology, Kyoto University Graduate 
School of Medicine from December in 2005 to December in 2012 were enrolled in this study. 
Patients took PROGRAF® (Astellas) capsules containing 1mg or 0.5mg tacrolimus. CTD patients 
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fulfilled criteria for each disease, namely, American College of Rheumatology (ACR) criteria for RA 
in 1987(9) or ACR/EULAR criteria in 2010(10), criteria for SLE(11), PM and DM(12) and for 
Polyarteritis Nodosa and microscopic polyangiitis(13).  
 
Clinical Information 
Information of age, sex, weight, serum creatinine and date of prescription, dosage, and serum level 
of TAC were obtained from clinical charts retrospectively by the system previously described(14).  
Information of prescription and dosage of corticosteroid was also obtained. TAC level data was 
obtained at least one week after prescription was initiated or changed. The data of concurrent use of 




The serum trough TAC level with 3mg TAC (around 12 hours after taking TAC) was used. TAC 
levels were quantified by two measurements according to measuring time; namely, microparticle 
enzyme immunoassay (MEIA, IMxTM-TACRO II, Abott) until May 2009 and chemiluminescent 
immunoassay (CLIA, ARCHITECT_TACRO, Abott) from May 2009. These measurements can 
quantify even low TAC levels (1.5~ and 0.5~ng/ml, respectively). When TAC levels were available 
for both measurements in a patient, data of CLIA with lower measuring limit of TAC levels was used. 
63 and 9 patients were quantified by CLIA and MEIA, respectively (hereafter termed as CLIA group 
and MEIA group, respectively). When multiple TAC levels with 3mg TAC were available, the mean 
of the levels was adopted. Calculations were performed based on logarithm of TAC levels to avoid 
negative level by linear regression model and excess influence of extreme data. 
 
Selection of SNPs and genotyping 
Rs776746, whose G allele determined CYP3A5*3, was selected based on previous studies. 
Genotyping was performed by the Taqman assay (Applied Biosystems).  
 
Statistical Analysis 
The association was analyzed between serum level of TAC in the patients and genotypes of rs776746, 
age, sex, weight, eGFR, whether the patients were affected with RA or with SLE by single or 
multiple linear regression analysis in each measurement separately. The overall associations were 
estimated by meta-analysis using inverse-variance method. P-value less than 0.05 was regarded as 
significant. These analyses were performed by R statistical software. 
 
Results 
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The summary of the subjects in the current study is shown in Table 1.  When we analyzed 
correlations between TAC level with 3mg TAC and age, sex, weight, eGFR, dosage or usage of 
corticosteroid or presence of RA or SLE by single linear regression analysis, none of them displayed 
overall significant associations (p≥0.083). However, because presence of RA showed a suggestive 
association in MEIA group (p=0.0091), we used presence of RA as a covariate. All the 72 patients 
were genotyped for rs776746 by Taqman assay. No deviation from Hardy-Weinberg equilibrium was 
observed (p=0.13). When the association between TAC level and genotypes of rs776746 was 
analyzed, we found a significant decreasing effect of the A allele of rs776746 on TAC level in 
patients with CTD (p=0.0038, Figure 1). Both MEIA and CLIA groups showed the comparable 
effect sizes (Table 2). Patients who were homozygote for the A allele had 16.9% and 35.0% lower 
level than those who were heterozygote and homozygote for G allele, respectively.  
 
Discussion 
The current study provided evidence that TAC level was strongly influenced by CYP3A5 in patients 
with CTD even taking only a small amount of TAC.  Our results showed the same direction of A 
allele of rs776746 and comparable effect sizes in the previous studies using patients of solid organ 
transplantation(5, 6). Disease-specific influence on TAC levels was not clear. Although a previous 
study has shown that a polymorphism in the ABCB1 gene was associated with the 
pharmacodynamics effect of TAC(15), there are also contradicting reports(6, 7). Thus, to our 
knowledge, the polymorphism of CYP3A5 is the only established polymorphism to influence TAC 
level. The dose-dependent association also supported the accuracy of the current study. These results 
should be replicated by a larger number of patients with CTD, also including other populations. 
Because the predictive model of TAC level is proposed in patients of organ transplantation, it will be 
interesting to construct a predictive model of TAC level in patients with CTD. 
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Figure 1. Association between TAC level and the polymorphism in CYP3A5 in patients with CTD. 
The obtained or inferred TAC levels adjusted for 3mg TAC are shown according to rs776746 
genotypes. Y axis is shown in log scale. The mean levels are 2.88, 3.57, and 5.10 ng/ml for AA, AG, 
GG genotypes, respectively. TAC levels were adjusted for MEIA group. 
 
 
Table 1. Summary of subjects in the current study. 
 Study Subjects 
Age* 48.94±17.24 
Sex Male 13 Female 59 
Disease** RA:22, SLE,43, DM3, PM2, PAN1, mPA1 
*mean±standard deviation 
** RA:Rheumatoid Arthritis, SLE: Systemic Lupus Erythematosus, DM: Dermatomyositis, PM: 
Polymyositis, PAN: Polyarteritis Nodosa, mPA: Microscopic Polyangiitis 
   
 
Table 2. Association between rs776746 and TAC level in multiple regression analysis. 
 Number Beta SE* P 
CLIA 63 0.106 0.041 0.012 
MEIA 9 0.161 0.12 0.22 
Overall 72 0.112 0.039 0.0038 
 Statistics adjusted by RA presence. *standard error 
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